Immune checkpoint inhibitors in cancer therapy
The discovery of immune checkpoint proteins such as PD-1/PDL-1 and CTLA-4 represents a
significant breakthrough in the field of cancer immunotherapy. Therefore, humanized …
significant breakthrough in the field of cancer immunotherapy. Therefore, humanized …
Turning cold tumors hot: from molecular mechanisms to clinical applications
J Zhang, D Huang, PE Saw, E Song - Trends in immunology, 2022 - cell.com
Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but most
'immune-cold'solid tumors are not responsive. The diversity of immune evasion mechanisms …
'immune-cold'solid tumors are not responsive. The diversity of immune evasion mechanisms …
Dostarlimab for primary advanced or recurrent endometrial cancer
Background Dostarlimab is an immune-checkpoint inhibitor that targets the programmed cell
death 1 receptor. The combination of chemotherapy and immunotherapy may have …
death 1 receptor. The combination of chemotherapy and immunotherapy may have …
Pembrolizumab in patients with microsatellite instability–high advanced endometrial cancer: results from the KEYNOTE-158 study
DM O'Malley, GM Bariani, PA Cassier… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE Pembrolizumab demonstrated durable antitumor activity in patients with
previously treated, advanced microsatellite instability–high or mismatch repair–deficient …
previously treated, advanced microsatellite instability–high or mismatch repair–deficient …
[HTML][HTML] Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study
M Maio, PA Ascierto, L Manzyuk, D Motola-Kuba… - Annals of …, 2022 - Elsevier
Background Pembrolizumab demonstrated durable antitumor activity in 233 patients with
previously treated advanced microsatellite instability high (MSI-H) or mismatch repair …
previously treated advanced microsatellite instability high (MSI-H) or mismatch repair …
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
The cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4)/B7 and programmed death 1
(PD-1)/programmed cell death-ligand 1 (PD-L1) are two most representative immune …
(PD-1)/programmed cell death-ligand 1 (PD-L1) are two most representative immune …
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
Immune checkpoint inhibitor (ICI) therapy targeting anti-programmed cell death-1 (anti-PD-
1) or its ligand (anti-PD-L1) is the backbone of numerous combination regimens aimed at …
1) or its ligand (anti-PD-L1) is the backbone of numerous combination regimens aimed at …
[HTML][HTML] Korean practice guidelines for gastric cancer 2022: an evidence-based, multidisciplinary approach
TH Kim, IH Kim, SJ Kang, M Choi, BH Kim… - Journal of gastric …, 2023 - ncbi.nlm.nih.gov
Gastric cancer is one of the most common cancers in Korea and the world. Since 2004, this
is the 4th gastric cancer guideline published in Korea which is the revised version of …
is the 4th gastric cancer guideline published in Korea which is the revised version of …
Pharmacogenomics: driving personalized medicine
Personalized medicine tailors therapies, disease prevention, and health maintenance to the
individual, with pharmacogenomics serving as a key tool to improve outcomes and prevent …
individual, with pharmacogenomics serving as a key tool to improve outcomes and prevent …
Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment
Microsatellite unstable (MSI) colorectal cancers (CRCs) are due to DNA mismatch repair
(MMR) deficiency and occurs in15% of non-metastatic diseases and 5% in the metastatic …
(MMR) deficiency and occurs in15% of non-metastatic diseases and 5% in the metastatic …